Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 94 | SFEBES2023 | Next issue

Society for Endocrinology BES 2023

Glasgow, UK
13 Nov 2023 - 15 Nov 2023

Card image cap
SfE BES is the UK's leading endocrinology meeting. It will return to Glasgow in 2023.

Oral Communications

Adrenal and Cardiovascular

ea0094oc5.1 | Adrenal and Cardiovascular | SFEBES2023

Urine steroid metabolomics as a diagnostic tool in endocrine hypertension

Prete Alessandro , Abdi Lida , Suntornlohanakul Onnicha , Lang Katharina , Riancho Julien , Lazkani Aida , Larsen Casper K. , Gimenez-Roqueplo Anne-Paule , Pecori Alessio , Tetti Martina , Monticone Silvia , Muller Lisa M. , Adolf Christian , Timmers Henri J.L.M. , Hampson Stephanie , Eisenhofer Graeme , Ceccato Filippo , Beuschlein Felix , Kabat Marek , Bertherat Jerome , Dennedy Conall , Davies Eleanor , Deinum Jaap , Reincke Martin , Paolo Rossi Gian , Mulatero Paolo , Amar Laurence , Zennaro Maria-Christina , Sitch Alice J. , Tino Peter , Biehl Michael , Taylor Angela E. , Arlt Wiebke

Background: Hypertension affects more than 30% of the adult population worldwide and is a major cardiovascular risk factor. Identifying secondary causes of hypertension is key to offering targeted treatment and mitigating adverse health outcomes. We tested the performance of urine steroid metabolomics (USM), the computational analysis of 24-hour urine steroid metabolome data by machine learning, for diagnosing endocrine hypertension.<str...

ea0094oc5.2 | Adrenal and Cardiovascular | SFEBES2023

Gain-of-function mutation F278C in MC2R results in reduced beta-1-arrestin recruitment and increased cAMP implicating impairment of S280 phosphorylation

Popat Dillon , Xu Ruoyan , McCormick Peter , Chan Li

The adrenocorticotrophin hormone (ACTH) receptor, also known as the melanocortin-2-receptor (MC2R), is a key mediator of cortisol synthesis in the adrenal gland. Over 40 loss-of-function MC2R mutations have been described to give rise to familial glucocorticoid deficiency type-1 (FGD1). In contrast, to date only one naturally occurring gain-of-function mutation, F278C, has been identified in a patient with ACTH-independent Cushing’s syndrome. Previous work has demonstrate...

ea0094oc5.3 | Adrenal and Cardiovascular | SFEBES2023

Imaging of adrenal aldosterone synthase expression in patients with primary aldosteronism – a first-in-human study with [18F]aldoview PET-CT

Arstad Erik , Sander Kerstin , Kurzawinski Tom , Awais Ramla , Twyman Frazer , Pritchcard Dylan , Glaser Matthias , Edaan Esra , Sirindil Fatih , Buhidma Yazead , Shortman Robert , Dickson John , Anderson Cameron , Chung Teng-Teng , Abdel-Aziz Tarek , Brown Morris , Williams Bryan

Background: Primary aldosteronism (PA) is the most common potentially curable cause of secondary hypertension and is a risk factor for cardiovascular morbidity and mortality. For patients with unilateral disease adrenalectomy can be curative. However, PA remains substantially underdiagnosed due the complex diagnostic pathway required to identify patients with unilateral disease, and the difficulties in accurate lateralization of the affected adrenal gland. Spe...

ea0094oc5.4 | Adrenal and Cardiovascular | SFEBES2023

Mild weight loss and activation of RAAS in gene-edited mice with a E958A knock-in mutation in the AF2-LBD domain of the mineralocorticoid receptor gene

Cole Timothy , Young Morag , Wang Vera , Yang Jun , Fuller Peter

The mineralocorticoid receptor (MR) has a modular domain structure containing a C-terminal ligand-binding domain (LBD) that consists of 11 α-helices (designated H1 to H12) organized in an antiparallel helical sandwich. The LBD undergoes a conformational change upon aldosterone binding such that H12 forms a stable interaction with helices 3, 4 and 5 to create an AF-2 domain, a hydrophobic cleft on the surface of the LBD, which serves as a docking platform for transcription...

ea0094oc5.5 | Adrenal and Cardiovascular | SFEBES2023

Identification of micrornas targeting the mineralocorticoid receptor with therapeutic potential in vascular cognitive impairment

Birch Lara , Fullerton Josie , MacKenzie Scott , Work Lorraine , Davies Eleanor

Hypertension is the most important risk factor in the development of cerebrovascular diseases including vascular cognitive impairment (VCI). Aldosterone is a key regulator of blood pressure, acting via the mineralocorticoid receptor (MR) in the kidney to promote sodium/water reabsorption. Elevated aldosterone, as in primary aldosteronism (PA) is a risk factor for cerebrovascular disease. In addition to its traditional role, the MR is expressed throughout the brain and vasculat...

ea0094oc5.6 | Adrenal and Cardiovascular | SFEBES2023

11βHSD1 inhibition improves cardiac function compared to standard therapy in a translational pig mode through regulation of extracellular matrix

Al Disi Sara , Ascione Raimondo , Johnson Tom , Sammut Eva , Domenico Bruno Vito , Khan Shazia , Singh Trisha , Baz Lopez Daniel , James Carol-Ann , Walker Brian , Mills Nicholas , Webster Scott , Freeman Adrian , Whittaker Andrew , Andrew Ruth , Gray Gillian

Glucocorticoids (GCs) protect cardiomyocytes immediately after myocardial infarction (MI), but GCs subsequently regenerated within the heart by 11β-hydroxysteroid dehydrogenase 1 (11βHSD1) are detrimental during infarct repair, with functional outcomes post-MI improved in mice lacking 11βHSD1. Pharmacological 11βHSD1 inhibition (AZD8329 50mg/kg, 11βHSD1i) was compared to standard clinical therapy (SCT) in a translational pig model (female, 11βHSD1...